Related references
Note: Only part of the references are listed.Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors
Marije Slingerland et al.
ANTI-CANCER DRUGS (2014)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Patricia A. J. Muller et al.
CANCER CELL (2014)
Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise
David A. Proia et al.
CANCER RESEARCH (2014)
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Susann Weissmueller et al.
CELL (2014)
Targeting tumour-supportive cellular machineries in anticancer drug development
Matthias Dobbelstein et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo Kian Hoe et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib
H. Landmann et al.
CELL DEATH & DISEASE (2014)
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
W. Hanel et al.
CELL DEATH AND DIFFERENTIATION (2013)
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
Mark A. Socinski et al.
CLINICAL CANCER RESEARCH (2013)
Drastic Effect of Germline TP53 Missense Mutations in LiFraumeni Patients
Yasmine Zerdoumi et al.
HUMAN MUTATION (2013)
NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones
David Siegel et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Geldanamycin and its derivatives as Hsp90 inhibitors
Magdalena Gorska et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2012)
Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
Weiwen Ying et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Multiple Stress Signals Activate Mutant p53 In Vivo
Young-Ah Suh et al.
CANCER RESEARCH (2011)
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
D. Li et al.
CELL DEATH AND DIFFERENTIATION (2011)
Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells
Dun Li et al.
MOLECULAR CANCER RESEARCH (2011)
Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
David A. Proia et al.
PLOS ONE (2011)
p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma
Brendan Doyle et al.
JOURNAL OF PATHOLOGY (2010)
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
Andelko Hrzenjak et al.
MOLECULAR CANCER (2010)
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Jennifer P. Morton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeting the dynamic HSP90 complex in cancer
Jane Trepel et al.
NATURE REVIEWS CANCER (2010)
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss
Tamara Terzian et al.
GENES & DEVELOPMENT (2008)
Molecular basis of the Li-Fraumeni syndrome:: an update from the French LFS families
G. Bougeard et al.
JOURNAL OF MEDICAL GENETICS (2008)
Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis
Chengkai Dai et al.
CELL (2007)
Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors
J-N Min et al.
ONCOGENE (2007)
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura et al.
NATURE (2007)
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
GA Lang et al.
CELL (2004)
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
KP Olive et al.
CELL (2004)